Decision-making about health technologies is complex. An aspect that is not often addressed is the potential impact of both hope and hype regarding these technologies. This article discusses the commercialization of hope and how “hope hype” can influence our decision-making. As health leaders have a pivotal role in how these types of decisions are made, opportunities for and suggestions related to structuring decision-making processes to critically engage with “hope hype” are also canvassed.
Get full access to this article
View all access options for this article.
References
1.
HochJS, Sabharwal. Informing Canada’s cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review. Curr Oncol. 2013;20(2):121–124.
SimpsonC. When hope makes us vulnerable: a discussion of patient-healthcare provider interactions in the context of hope. Bioethics. 2004;18(5):428–447.
DrahosP. Trading in public hope. Ann Am Acad. 2004;592(1):18–38.
6.
BrownPR. The dark side of hope and trust: constructed expectations the value-for-money regulation of new medicines. Health Soc Rev. 2011;20(4):410–422.
7.
ZizekS.Interview In: The Children of Men. Los Angeles, CA: Universal Pictures; 2006.
8.
DeyoRAPatrickDL. Hope or Hype: The Obsession With Medical Advances and the High Cost of False Promises. New York, NY: AMACOM; 2005.
9.
KirbyJSomersESimpsonCMcPheeJ. The public funding of expensive cancer therapies: synthesizing the “3Es”—evidence, economics, and ethics. Organizational Ethics. 2007;4(2):97–108.
10.
SinclairSHagenNAChambersC. Accounting for reasonableness: exploring the personal internal framework affecting decisions about cancer drug funding. Health Policy. 2008;86(2-3):381–390.
